

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMM United States Patent and Trademark office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

CONFIRMATION NO. APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 08/873,597 06/12/1997 JON FAIZ KAYYEM A-64558-1/RF 2066

7590

07/07/2006

ROBIN M SILVA FLEHR HOHBACH TEST ALBRITTON & HERBERT FOUR EMBARCADERO CENTER **SUITE 3400** SAN FRANCISCO, CA 941114187

EXAMINER

FORMAN, BETTY J

ART UNIT PAPER NUMBER

1634

DATE MAILED: 07/07/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Office Action Summary	08/873,597	KAYYEM, JON FAIZ	
	Examiner	Art Unit	
	BJ Forman	1634	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet wit	h the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNIC 36(a). In no event, however, may a re will apply and will expire SIX (6) MONIC c, cause the application to become AB/	ATION. ply be timely filed THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 20 Ju	une 2005.		
	action is non-final.		
3) Since this application is in condition for allowa		ers, prosecution as to the merits is	
closed in accordance with the practice under E	·	• •	
Disposition of Claims			
4) Claim(s) 19-22,26,33-35 and 39-45 is/are pend	ding in the application.		
4a) Of the above claim(s) is/are withdraw	- ''		
5) Claim(s) is/are allowed.			
6) Claim(s) 19-22,26,33-35 and 39-45 is/are rejection	cted.		
7)☐ Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and/o	r election requirement.		
Application Papers			
9) The specification is objected to by the Examine	er.		
10) The drawing(s) filed on is/are: a) □ acc	epted or b)□ objected to b	y the Examiner.	
Applicant may not request that any objection to the	drawing(s) be held in abeyand	e. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is objected to. See 37 CFR 1.121(d).	
11)☐ The oath or declaration is objected to by the Ex	caminer. Note the attached	Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1 Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority 	s have been received. s have been received in Aprity documents have been i	pplication No	
application from the International Bureau * See the attached detailed Office action for a list		eceived.	
Attachment(s)			
) Notice of References Cited (PTO-892)	4) Interview Su	mmary (PTO-413)	
P) Notice of Draftsperson's Patent Drawing Review (PTO-948) Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		/Mail Date ormal Patent Application (PTO-152) -	

Application/Control Number: 08/873,597

Art Unit: 1634

DETAILED ACTION

Page 2

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 20 June 2005 has been entered.

Information Disclosure Statement

2. The information disclosure statement (IDS) submitted on 20 June 2005 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Art Unit: 1634

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 19-22, 26, 33-35 and 39-45 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 10 of U.S. Patent No. 7,014,992 in view of Okano et al (U.S. Patent No. 5,434,049. Although the conflicting claims are not identical, they are not patentably distinct from each other because both patent claim and the instant claims are drawn to electrode immobilized nucleic acids wherein the nucleic acids are immobilized covalently via an insulator. The claims merely differ in that the instant claims are drawn to two electrodes. However, multiple electrode substrates for nucleic acid immobilization was well known in the art at the time the claimed invention was made as taught by Okano et al who teach that multiple electrodes provide for simultaneous detection of a plurality of nucleotide targets (Abstract and Column 2, lines 35-57). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to modify the '049 electrode by using additional electrodes as taught by Okano et al. One of ordinary skill in the art would have been motivated to do so for the expected benefit of for detecting of a plurality of nucleotide targets simultaneously as taught by Okano et al (Abstract and Column 2, lines 35-57).

5. Claims 19-22, 26, 33-35 and 39-45 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 22, 26-27, 30-35, 37-45 of copending Application No. 09/452,277 in view of Okano et al. (U.S. Patent No. 5,434,049. Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to electrode immobilized nucleic acids wherein the nucleic acids are immobilized covalently via an insulator. The claim sets merely

Art Unit: 1634

differ in the arrangement of limitations within the claim sets and further in that the instant claims are drawn to two electrodes. However, multiple electrode substrates for nucleic acid immobilization was well known in the art at the time the claimed invention was made as taught by Okano et al who teach that multiple electrodes provide for simultaneous detection of a plurality of nucleotide targets (Abstract and Column 2, lines 35-57). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to modify the '277 electrode by using additional electrodes as taught by Okano et al. One of ordinary skill in the art would have been motivated to do so for the expected benefit of for detecting of a plurality of nucleotide targets simultaneously as taught by Okano et al (Abstract and Column 2, lines 35-57).

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (571) 272-0741. The examiner can normally be reached on 6:00 TO 3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 08/873,597 Page 5

Art Unit: 1634

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

BJ Formen Primary Examiner Art Unit 1634

5 July 2006